BioSpace News Archive

Renibus Therapeutics® today announced publication in E-Clinical Medicine, part of The Lancet Discovery Science, of results from the Phase 2 study evaluating RBT-1, the Company’s first-in-a-new-class preconditioning agent, under investigation to reduce post-operative complications following cardiothoracic surgery.

Sonendo, Inc. announced a partnership agreement with Dental Purchasing Group, a member-driven group purchasing organization that provides independent and group dental practices with cost savings programs.

LadRx Corporation issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.

Today, Pendulum Therapeutics , the leading microbiome biotech company pioneering the next frontier of metabolic health, announced that former Mayo Clinic Medical Director and Executive Director for Integrative Medicine at Duke University, Adam Perlman, MD, MPH, FACP, has joined the company as Chief Medical Officer.

Cleerly, the company working to create a new standard of care for the diagnosis of heart disease, today announced the launch of Cleerly ISCHEMIA, which recently received U.S. Food and Drug Administration (FDA) 510(k) medical device clearance.

Milla Pharmaceuticals Inc., an A.forall company, announced that its partner, Woodward Pharma Services LLC, has just commercialized its Supplemental Abbreviated New Drug Application approval from the U.S. Food and Drug Administration for a generic version of Sodium Acetate Injection 4 mEq/mL marketed by Fresenius Kabi USA LLC.

SOHM, Inc. (OTC PINK: SHMN) (the “Company”) announces today the Company has filed a provisional patent application on its ABBIE “Smart Gene-Editing” platform that uses the latest enzymes and guide RNAs to resolve off-target gene-editing limitations.

Glaukos Corporation today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.

Precision BioSciences, Inc. today announced completion of a strategic transaction with TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.

Levity Products, Inc., an innovative provider of catheter stabilizers, today announced a strategic partnership with Domrex Pharma, Inc., a North American leader in healthcare product distribution.